Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel
Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decreas...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2022-02-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article |
| _version_ | 1818898966623813632 |
|---|---|
| author | Jennifer Kertes Sharon Baruch Gez Yaki Saciuk Lia Supino-Rosin Naama Shamir Stein Miri Mizrahi-Reuveni Anat E. Zohar |
| author_facet | Jennifer Kertes Sharon Baruch Gez Yaki Saciuk Lia Supino-Rosin Naama Shamir Stein Miri Mizrahi-Reuveni Anat E. Zohar |
| author_sort | Jennifer Kertes |
| collection | DOAJ |
| description | Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decrease over time, describe the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. Mean IgG levels steadily decreased over the 6-month period in the total tested population and in all age groups. An inverse relationship was found between IgG titer and subsequent PCR-positive infection. Persons vaccinated during the first 2 months of the campaign were more likely to become infected than those subsequently vaccinated. The vaccinated group >60 years of age had lower initial IgG levels and were at greater risk for infection. The findings support the decision to add a booster vaccine for persons >60 years of age. |
| first_indexed | 2024-12-19T19:40:28Z |
| format | Article |
| id | doaj.art-327900edfecc4372a8cbd7f4937ce2b5 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-19T19:40:28Z |
| publishDate | 2022-02-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-327900edfecc4372a8cbd7f4937ce2b52022-12-21T20:08:16ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592022-02-0128233834610.3201/eid2802.211834Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, IsraelJennifer KertesSharon Baruch GezYaki SaciukLia Supino-RosinNaama Shamir SteinMiri Mizrahi-ReuveniAnat E. ZoharIsrael experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decrease over time, describe the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. Mean IgG levels steadily decreased over the 6-month period in the total tested population and in all age groups. An inverse relationship was found between IgG titer and subsequent PCR-positive infection. Persons vaccinated during the first 2 months of the campaign were more likely to become infected than those subsequently vaccinated. The vaccinated group >60 years of age had lower initial IgG levels and were at greater risk for infection. The findings support the decision to add a booster vaccine for persons >60 years of age.https://wwwnc.cdc.gov/eid/article/28/2/21-1834_articleCOVID-19coronavirus diseasesevere acute respiratory syndrome coronavirus 2SARS-CoV-2coronavirusesviruses |
| spellingShingle | Jennifer Kertes Sharon Baruch Gez Yaki Saciuk Lia Supino-Rosin Naama Shamir Stein Miri Mizrahi-Reuveni Anat E. Zohar Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel Emerging Infectious Diseases COVID-19 coronavirus disease severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 coronaviruses viruses |
| title | Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel |
| title_full | Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel |
| title_fullStr | Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel |
| title_full_unstemmed | Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel |
| title_short | Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel |
| title_sort | effectiveness of mrna bnt162b2 vaccine 6 months after vaccination among patients in large health maintenance organization israel |
| topic | COVID-19 coronavirus disease severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 coronaviruses viruses |
| url | https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article |
| work_keys_str_mv | AT jenniferkertes effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT sharonbaruchgez effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT yakisaciuk effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT liasupinorosin effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT naamashamirstein effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT mirimizrahireuveni effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael AT anatezohar effectivenessofmrnabnt162b2vaccine6monthsaftervaccinationamongpatientsinlargehealthmaintenanceorganizationisrael |